Silence Therapeutics
6 hedge funds and large institutions have $56.4M invested in Silence Therapeutics in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.95% less ownership
Funds ownership: 8.51% → 7.56% (-0.95%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $7.46M
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (USA)
New York
|
-$7.44M |
| 2 |
Morgan Stanley
New York
|
-$14.4K |
| 3 |
SG Americas Securities
New York
|
-$1.12K |
SLN Hedge Fund Activity: Q2 2021 in Review
6 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2021, worth a combined $56.4M — up 0.84% from $55.9M a quarter earlier.
Fund positioning in SLN was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $7.44M.
- 6 institutional investors held Silence Therapeutics (SLN) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $56.4M of Silence Therapeutics stock for Q2 2021, up 0.84% quarter-over-quarter.
- 0 funds opened new Silence Therapeutics positions in Q2 2021 and 0 closed out.
- The largest Silence Therapeutics seller in Q2 2021 was Lombard Odier Asset Management (USA), an estimated $7.44M sold.
Based on aggregated 13F filings for Q2 2021.